Anticholinergic medication burden and cognitive function in participants of the ASPREE study
Authors:
- Jonathan C. BroderJBJonathan C. Broder
- Joanne RyanJRJoanne Ryan
- Raj C. ShahRSRaj C. Shah
- Jessica E. LockeryJLJessica E. Lockery
- Suzanne G. OrchardSuzanne G. Orchard
- Julia F.‐M. Gilmartin‐ThomasJGJulia F.‐M. Gilmartin‐Thomas
- Michelle A. FravelMFMichelle A. Fravel
- Alice J. OwenAlice J. Owen
- Robyn L. WoodsRWRobyn L. Woods
- Rory WolfeRWRory Wolfe
- Anne M. MurrayAMAnne M. Murray
- 14 December 2021
- journal article
- research article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 42 (2) , 134-144
Abstract
Study Objective: What is the association between anticholinergic burden and specific domains of cognitive function in older adults who are initially without major cognitive impairment?Design: Post‐hoc analysis of longitudinal observational data from the ASPirin in Reducing Events in the Elderly (ASPREE) study.Patients: 19,114 participants from Australia and the United States aged 70 years and older (65 years and older for US minorities) were recruited and followed for a median of 4.7 years. At enrollment, participants were free of known cardiovascular disease, major physical disability, or dementia.Measurements: Cognitive assessments administered at baseline and biennially at follow‐up visits included the Modified Mini‐Mental State examination (3MS), Hopkins Verbal Learning Test–Revised (HVLT‐R) delayed recall, Controlled Oral Word Association Test (COWAT), and Symbol Digit Modalities Test (SDMT). Anticholinergic burden was calculated at baseline using the Anticholinergic Cognitive Burden (ACB) scale and grouped as scores of 0 (no burden), 1‐2 (low to moderate), or 3+ (high).Main Results: Linear mixed effects models were used to assess the relationship between ACB score and cognition over time. After adjusting for sex, age, education, minority status, smoking status, hypertension, diabetes, depression, chronic kidney disease, country, and frailty, participants with a high ACB score had worse performance over time for 3MS (Adjusted [Adj] B=‐0.092, P=0.034), HVLT‐R delayed recall (Adj B=‐0.104, P<0.001), COWAT (Adj B=‐0.151, P<0.001), and SDMT (Adj B=‐0.129, P=0.026), than participants with an ACB score of 0. A low to moderate ACB score was also associated with worse performance over time for HVLT‐R delayed recall (Adj B=‐0.037, P=0.007) and COWAT (Adj B=‐0.065, P=0.003), compared to those with no ACB.Conclusions: Anticholinergic burden predicts worse cognitive function over time in initially dementia‐free older adults, particularly for executive function (COWAT) and episodic memory (HVLT‐R).Keywords
Funding Information
- Victorian Cancer Agency
- National Institutes of Health (U01AG029824, U19AG062682)
- National Health and Medical Research Council (1127060, 334047)
- Monash University
This publication has 34 references indexed in Scilit:
- Anticholinergic Medication Use and Cognitive Impairment in the Older Population: The Medical Research Council Cognitive Function and Ageing StudyJournal of the American Geriatrics Society, 2011
- The cognitive impact of anticholinergics: A clinical reviewClinical Interventions in Aging, 2009
- Cumulative Anticholinergic Exposure Is Associated with Poor Memory and Executive Function in Older MenJournal of the American Geriatrics Society, 2008
- STOPP (Screening Tool of Older Persons' potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers' criteriaAge and Ageing, 2008
- Antimuscarinic Drugs for Overactive Bladder and Their Potential Effects on Cognitive Function in Older PatientsJournal of the American Geriatrics Society, 2005
- Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugsAnnals of Neurology, 2003
- The reliability of cluster and switch scores for the controlled oral word association testArchives of Clinical Neuropsychology, 2003
- Hopkins Verbal Learning Test – Revised: Normative Data and Analysis of Inter-Form and Test-Retest ReliabilityThe Clinical Neuropsychologist, 1998
- Scopolamine effects on memory, language, visuospatial praxis and psychomotor speedPsychopharmacology, 1990
- Systematic regional differences in the cholinergic innervation of the primate cerebral cortex: Distribution of enzyme activities and some behavioral implicationsAnnals of Neurology, 1986